Effects of IRL 1620 on Tumor Blood Flow
Author Information
Author(s): Cemazar M, Wilson I, Prise V E, Bell K M, Hill S A, Tozer G M
Primary Institution: Gray Cancer Institute, Mount Vernon Hospital
Hypothesis
The endothelin B receptor agonist IRL 1620 can selectively modify blood flow in tumors.
Conclusion
IRL 1620 significantly reduces blood flow in the P22 tumor, indicating its potential for therapeutic use in cancer treatment.
Supporting Evidence
- IRL 1620 caused a 50% reduction in blood flow in P22 tumors.
- Blood flow returned to control levels within approximately 30 minutes after treatment.
- Vascular resistance in tumors increased significantly after IRL 1620 administration.
Takeaway
This study shows that a drug called IRL 1620 can make tumors shrink by cutting off their blood supply, which might help in cancer treatment.
Methodology
The study used laser Doppler flowmetry and radiolabelled iodoantipyrine to measure blood flow in tumors and normal tissues in rats.
Limitations
The study was conducted in rats, which may not fully represent human responses.
Participant Demographics
10- to 12-week-old male BDIX rats and 8- to 10-week-old female CBH/CBi rats.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website